#symfi

[pozmagazine]

FDA OKs Symfi, Mylan’s Third Cut-Price Single-Tablet HIV Regimen

The Food and Drug Administration (FDA) has approved Mylan’s Symfi (efavirenz 600 mg/lamivudine/tenofovir disoproxil fumarate), a single-tablet antiretroviral (ARV) regimen for the treatment of HIV among adults and children who weigh at least 40 kilograms (88 pounds).